Skip to main content

$0.007 0.001 (16.67%)

High

$0.01

Low

$0.01

Trades

19

Turnover

$1,131

Volume

188,484
30 June 2023 at 4:10pm
Register to track ATH and receive email alerts.
Subject
ATH Ann: Investor Presentation

ATH Ann: ATH to present at MST Rare Diseases Rich Returns Forum

ATH Ann: ATH starts 2nd Phase 2 Study in Rare Parkinsonian Disorder

ATH Ann: First Patient Enrolled in Australia in global Phase 2 Trial

ATH Ann: Appendix 4C and Quarterly Cash Flow Report

ATH Ann: bioMUSE Wearable Sensor Data presented at AAN Annual Meeting

ATH Ann: Notification of cessation of securities - ATH

ATH Ann: First Patient Enrolled in UK in Phase II Clinical Trial

ATH Ann: Change in substantial holding

ATH Ann: Notice Under Section 708A

ATH Ann: Application for quotation of securities - ATH

ATH Ann: First Patient Enrolled in USA in Phase II Clinical Trial

ATH Ann: Proposed issue of securities - ATH

ATH Ann: US patent grant and license agreement

ATH Ann: Investor Webinar Presentation

ATH Ann: First Patient Enrolled in Europe in Phase II Clinical trial

ATH Ann: Half Yearly Report and Accounts

ATH Ann: Regulatory approval for Phase II trial in France and Austria

ATH Ann: Change in substantial holding

ATH Ann: Notification of cessation of securities - ATH

ATH Ann: Appendix 4C and Quarterly Cash Flow Report

ATH Ann: ATH434 Prevents Brain Cell loss in Parkinsons Animal Model

ATH Ann: ATH434 Clinical Trial Launched in Italy

ATH Ann: ATH434 clinical trial launched in the US

ATH Ann: ADS ratio change

ATH Ann: Alterity to participate in Sachs Neuroscience Conference

ATH Ann: New US patent for compounds to treat neurodegeneration

ATH Ann: Change of Director's Interest Notice x 4

ATH Ann: Notification of cessation of securities - ATH

ATH Ann: Change in substantial holding

ATH Ann: ATH Constitution (amended)

ATH Ann: Results of Annual General Meeting

ATH Ann: Chairman's Address 2022 Annual General Meeting

ATH Ann: ATH Annual General Meeting Presentation

ATH Ann: Presentation of bioMUSE urinary symptom profile data

ATH Ann: Change in substantial holding

ATH Ann: Change in substantial holding

ATH Ann: Appendix 4C and Quarterly Cash Flow Report

ATH Ann: Presentation of bioMUSE MRI data

ATH Ann: ATH434 Clinical Trial launched in Australia

ATH Ann: Notice of Annual General Meeting/Proxy Form

ATH Ann: Change in substantial holding

ATH Ann: Wearable Sensor Data from bioMUSE Natural History Study

ATH Ann: Notice Under Section 708A

ATH Ann: Application for quotation of securities - ATH

ATH Ann: Proposed issue of securities - ATH

ATH Ann: US FDA Approval for IND Application for ATH434 for MSA

ATH Ann: Alterity Form 20-F and XBRL data filed with SEC

ATH Ann: Appendix 4G and Corporate Governance Statement 2022

ATH Ann: Appendix 4E & Annual Report 2022

Register to track ATH and receive email alerts.

Similar Companies

CSL ...
CSL
CUV
IMM
IMU
MSB
OPT
PAR
PYC
RAC
TLX